gene

FUS

Entity Detail — Knowledge Graph Node

Understanding Entity Pages

This page aggregates everything SciDEX knows about FUS: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.

2407Connections

30Hypotheses

13Analyses

50Outgoing

50Incoming

0Experiments

15Debates

Summary

FUS is a gene implicated in neurodegeneration research. Key relationships include: associated with, therapeutic target, interacts with. Associated with AD, ALI, ALS. Connected to 507 entities in the SciDEX knowledge graph.

View on Wiki →

No AI portrait yet

🧬 Gene Info

Gene Symbol	FUS
Full Name	Fused in Sarcoma
Chromosome	16p11.2.
Protein Type	Protein
Function	is an important component in the neurobiology of neurodegenerative diseases.
Pathways	Blood-Brain Barrier, Hippo Pathway, Oxidative Stress, Sod1, Tdp-43
UniProt ID	Search UniProt
GeneCards	FUS
Human Protein Atlas	FUS
Associated Diseases	AD, Aging, ALI, als
Known Drugs/Compounds	ADUCANUMAB, Antisense Oligonucleotide, Rna Oligonucleotides, RNA oligonucleotides
Interactions	ACTB, Actin, AD, AGING, ALPHA-SYNUCLEIN, ALS
SciDEX Hypotheses	ASO-Mediated Exon Skipping to Restore FUS-TAZ Chap FUS Phase Separation Dominance in FTD-TDP: Aberran Arginine Methylation Loss on FUS RGG Domains Drive (+6 more)
KG Connections	1564 knowledge graph edges
Databases	GeneCards NCBI Gene HPA STRING

🧬 3D Structure Comparison — FUS Experimental (PDB) vs Predicted (AlphaFold) — click to expand

📄 Experimental Structure

4FDD — X-ray / Cryo-EM

🔮 AI Predicted Structure

P35637 — AlphaFold

Left: Experimental structure from RCSB PDB | Right: AI-predicted structure from AlphaFold | Powered by Mol*

Wiki Pages (16)

Knowledge base pages for this entity

Canonical Page

Pathway Diagram

flowchart TD
    FUS(["FUS"])
    TARDBP(["TARDBP"])
    Amyotrophic_Lateral_Sclerosis["Amyotrophic Lateral Sclerosis"]
    ALS(["ALS"])
    AMYOTROPHIC_LATERAL_SCLEROSIS(["AMYOTROPHIC LATERAL SCLEROSIS"])
    Als["Als"]
    SOD1(["SOD1"])
    MECP2(["MECP2"])
    GENES(["GENES"])

    FUS -->|"associated with"| TARDBP
    FUS -->|"associated with"| Amyotrophic_Lateral_Sclerosis
    ALS -->|"associated with"| FUS
    FUS -->|"risk factor for"| Amyotrophic_Lateral_Sclerosis
    FUS -->|"associated with"| AMYOTROPHIC_LATERAL_SCLEROSIS
    FUS -->|"interacts with"| Amyotrophic_Lateral_Sclerosis
    FUS -->|"associated with"| Als
    FUS -->|"causes"| Amyotrophic_Lateral_Sclerosis
    FUS -->|"associated with"| SOD1
    FUS -->|"regulates"| MECP2
    FUS -->|"interacts with"| ALS
    FUS -->|"activates"| ALS
    FUS -->|"associated with"| GENES
    FUS -->|"associated with"| ALS
    FUS -->|"interacts with"| AMYOTROPHIC_LATERAL_SCLEROSIS

    style FUS fill:#006494,stroke:#4fc3f7,stroke-width:3px,color:#e0e0e0

Outgoing (1241)

Target	Relation	Type	Str
FUS	encodes	protein	0.00
Amyotrophic Lateral Sclerosis	associated_with	disease	1.00
TARDBP	associated_with	gene	1.00
DEMENTIA	associated_with	disease	0.98
Phase Transition	involved_in	process	0.95
Neurodegeneration	associated_with	process	0.95
TDP-43	interacts_with	gene	0.95
FTD	associated_with	disease	0.95
ALS	associated_with	disease	0.95
Stress Granule Transcriptome	modulates	phenotype	0.95
liquid phase condensation	involved_in	process	0.95
Early-Onset ALS	risk_factor_for	phenotype	0.93
motor neuron death	contributes_to	process	0.90
H1F2	interacts_with	protein	0.90
Stress Granules	associated_with	process	0.90
Histone H1.2	interacts_with	protein	0.90
oxidative stress response	participates_in	pathway	0.90
HSPA8	regulates	gene	0.90
Neuromuscular Synapses	regulates	phenotype	0.90
familial ALS	causes	disease	0.90
ALS/FTD	associated_with	disease	0.90
G3BP1 stress granules	recruited_to	process	0.90
NEURON	associated_with	gene	0.90
protein misfolding	causes	pathway	0.90
HSPA8 mRNA Dendritic Localization	regulates	process	0.90
Proteostasis	regulates	process	0.90
FRONTOTEMPORAL DEMENTIA	associated_with	disease	0.90
Stress Granules	interacts_with	process	0.90
Amyotrophic Lateral Sclerosis	biomarker_for	disease	0.90
Motor Neuron Degeneration	contributes_to	process	0.90
ftd	causes	disease	0.90
Liquid-Liquid Phase Separation	regulates	phenotype	0.90
tight junction disassembly	causes	mechanism	0.90
RNA Splicing	regulates	phenotype	0.90
TAU	associated_with	gene	0.90
ALS-FTD	risk_factor_for	disease	0.90
Transcriptional Regulation	regulates	phenotype	0.90
ZO-1 phosphorylation	causes	mechanism	0.90
anti-amyloid antibody brain penetration	enhances	mechanism	0.90
Src kinase	activates	protein	0.90
Akt phosphorylation	activates	mechanism	0.90
BBB opening	causes	mechanism	0.90
als	causes	disease	0.90
Cytoplasmic Mislocalization	associated_with	phenotype	0.90
pathological aggregation	involved_in	process	0.90
Pathological Aggregation	associated_with	phenotype	0.90
Nuclear Localization	involved_in	process	0.90
Motor Neuron Degeneration	causes	disease	0.90
frontotemporal dementia	associated_with	disease	0.90
Ftld-Fet	component_of	disease	0.90

Incoming (1166)

Source	Relation	Type	Str
FUS	encodes	gene	0.00
entities-histone-modifications	interacts_with	wiki	0.00
entities-mitochondrial-dynamics	interacts_with	wiki	0.00
ALS	associated_with	disease	1.00
Rna Oligonucleotides	interacts_with	compound	0.90
Rna Oligonucleotides	inhibits	compound	0.90
RNA oligonucleotides	binds	compound	0.90
DIPEPTIDE REPEAT PROTEINS	interacts_with	protein	0.85
KAPB2	interacts_with	protein	0.85
RNA oligonucleotides	targets	compound	0.85
Mistranslation	exacerbates	process	0.85
ALS	interacts_with	entity	0.82
ALS	accumulates_in	gene	0.80
Stress Granules	mediates	process	0.80
DNA	disrupts	gene	0.80
Antisense Oligonucleotide	therapeutic_target	drug	0.80
Chronological Ageing	modulates	process	0.80
MATR3	interacts_with	protein	0.75
ALS	activates	disease	0.74
ALZHEIMER'S DISEASE	associated_with	disease	0.72
BACE1	interacts_with	gene	0.70
AMYOTROPHIC LATERAL SCLEROSIS	transports	disease	0.70
APP	interacts_with	gene	0.70
ATG5	regulates	gene	0.70
FTD	associated_with	disease	0.70
APOE	mediates	gene	0.70
ACHE	associated_with	gene	0.70
MICRORNAS	modulates	gene	0.70
DNA	causes	gene	0.70
GAIN	causes	gene	0.70
C9ORF72	interacts_with	gene	0.70
entities-c9orf72-protein	interacts_with	wiki	0.70
C9ORF72	associated_with	gene	0.70
IFN	associated_with	gene	0.70
NEURODEGENERATION	therapeutic_target	gene	0.70
DNA	accumulates_in	gene	0.70
FRONTOTEMPORAL DEMENTIA	interacts_with	disease	0.65
UBIQUITIN	associated_with	protein	0.65
ALZHEIMER	associated_with	gene	0.65
FRONTAL	regulates	brain_region	0.65
AMYOTROPHIC LATERAL SCLEROSIS	causes	disease	0.65
TDP-43	phosphorylates	gene	0.65
CORTEX	regulates	brain_region	0.65
CORTEX	transports	brain_region	0.65
NEURODEGENERATION	interacts_with	gene	0.60
FIG4	associated_with	gene	0.60
UBIQUITIN	regulates	gene	0.60
SRC	expressed_in	gene	0.60
ALS2	associated_with	gene	0.60
PI3K	therapeutic_target	gene	0.60

Targeting Hypotheses (30)

Hypotheses where this entity is a therapeutic target

Hypothesis	Score	Disease	Analysis
VHH-Fc Fusion Constructs with Separate BBB-Targeting Moiety	0.750	neurodegeneration	Blood-brain barrier antibody transport m
H3: G3BP1 as Nucleation Hub for TDP-43/FUS Seeding	0.743	neurodegeneration	How do pathological stress granules tran
SGMS1-Driven Sphingomyelin Accumulation Impairs BACE1 Lysoso	0.734	neurodegeneration	What molecular mechanisms link elevated
ASO-Mediated Exon Skipping to Restore FUS-TAZ Chaperone Axis	0.720	neurodegeneration	How does FUS loss-of-function in TAZ reg
GluN2B Tonic Activity Suppresses Glymphatic Perfusion Via Va	0.700	neuroscience	GluN2B-Mediated Thalamocortical Control

FUS Phase Separation Dominance in FTD-TDP: Aberrant Condensa	0.683	frontotemporal-dementia	-
DRP1 S616 Hyperphosphorylation and MFN2 Downregulation Creat	0.680	neurodegeneration	-
Arginine Methylation Loss on FUS RGG Domains Drives Irrevers	0.680	als	Biophysical Determinants Shifting FUS/TD
LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Tr	0.650	neurodegeneration	Blood-brain barrier antibody transport m
Autophagosome-Lysosome Fusion Defects as Primary Driver of α	0.630	neurodegeneration	Gap 006 analysis (archived stub)
RNA-binding protein condensate maturation from reversible ph	0.626	neurodegeneration	Biophysical Determinants Shifting FUS/TD
mutant FUS effects split between motor-neuron intrinsic stre	0.626	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Optogenetic viral vector delivery via tFUS-mediated blood-br	0.622	alzheimers	Circuit-level neural dynamics in neurode
Designer TRAK1-KIF5 fusion proteins accelerate therapeutic m	0.621	neurodegeneration	Mitochondrial transfer between astrocyte
FUS Mutations Alter Stress Granule Material Properties to Co	0.613	neurodegeneration	How do pathological stress granules in n
Cell-state stratification is required to resolve Cell-Autono	0.612	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Cell-state stratification is required to resolve Biophysical	0.612	neurodegeneration	Biophysical Determinants Shifting FUS/TD
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Cell-Autonomous vs Non-Cell-Autonomous M
Perturbation-first validation should precede therapeutic cla	0.608	neurodegeneration	Biophysical Determinants Shifting FUS/TD
Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-	0.600	neurodegeneration	What are the neuron-specific effects of
Gamma Entrainment Synergy: HBOT-Enhanced Cerebral Perfusion	0.583	neurodegeneration	What are the optimal oxygen pressure, du
Closed-Loop Hippocampal TFUS for Gamma Network Target Engage	0.575	alzheimers	Closed-loop transcranial focused ultraso
Fusing IGFBPL1 to IGF-1 for Receptor-Mediated BBB Transcytos	0.552	drug-delivery	Can IGFBPL1 therapeutics effectively cro
Small-Molecule FUS Nuclear Import Correctors Rescue Motor Ne	0.550	neurodegeneration	Test Hypothesis Fixtures
GPP Repeat Peptide-Fc Fusion for Enhanced Brain Penetration	0.550	neurodegeneration	Blood-brain barrier antibody transport m
Computational Model-Optimized TFUS Parameters for Interneuro	0.545	alzheimers	Closed-loop transcranial focused ultraso
Low-Intensity tFUS Modulation of EC-DG/EC-CA1 Perforant Path	0.540	alzheimers	Closed-loop transcranial focused ultraso
Sleep-Stage TFUS to Restore SWR-Gamma Coupling and Memory Co	0.525	alzheimers	Closed-loop transcranial focused ultraso
Gamma/tFUS Entrainment as Biomarker Modulator of Neuroinflam	0.520	alzheimers	Closed-loop transcranial focused ultraso
TFUS-Gamma Entrainment Synergizes with Anti-Amyloid Immunoth	0.505	alzheimers	Closed-loop transcranial focused ultraso

Mentioning Analyses (13)

Scientific analyses that reference this entity

Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Ag

neurodegeneration | 2026-04-27 | 4 hypotheses Top: 0.680

Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular De

neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.626

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

molecular neurobiology | 2026-04-25 | 28 hypotheses Top: 0.865

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

neurodegeneration | 2026-04-14 | 1 hypotheses Top: 0.720

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

neurodegeneration | 2026-04-13 | 2 hypotheses Top: 0.584

Experiments (0)

Experimental studies targeting or related to this entity

Experiment	Type	Disease	Score	Feasibility	Model	Status	Est. Cost
No experiments found

Related Papers (0)

Scientific publications cited in analyses involving this entity

Title & PMID	Authors	Journal	Year	Citations
No papers found

Debates (15)

Multi-agent debates referencing this entity

What are the biophysical determinants — RNA binding stoichiometry, post-translat

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

What are the relative contributions of cell-autonomous motor neuron mechanisms v

closed · Rounds: 4 · Score: 0.67 · 2026-04-28

Debate: Liquid-to-Solid Transition Pathology Reveals Granule Weak Points

closed · Rounds: 4 · Score: 0.58 · 2026-04-27

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

closed · Rounds: 4 · Score: 0.66 · 2026-04-25

What mechanisms govern antibody transport across the blood-brain barrier and how

closed · Rounds: 4 · Score: 0.82 · 2026-04-22

The study shows stress granules are dynamic and reversible assemblies, but in ne

closed · Rounds: 4 · Score: 0.84 · 2026-04-22

The study shows that G3BP1 ubiquitination inhibits LLPS in vitro, but the molecu

closed · Rounds: 4 · Score: 0.79 · 2026-04-21

While the study identifies G3BP1 as a central node triggering phase separation,

closed · Rounds: 4 · Score: 0.76 · 2026-04-21

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate

closed · Rounds: 4 · Score: 0.81 · 2026-04-16

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

closed · Rounds: 4 · Score: 0.63 · 2026-04-13

Related Research

Hypotheses and analyses mentioning FUS in their description or question text

FUS

Understanding Entity Pages

Summary

Wiki Pages (16)

FUS — Fused in Sarcoma

FUS Gene-Mechanism-Therapy Causal Chain — ALS/FTD

FUS Mutations in Amyotrophic Lateral Sclerosis

FUS Protein in Amyotrophic Lateral Sclerosis

FUS (Fused in Sarcoma) Protein

FUS-Targeting Therapies for Amyotrophic Lateral Sclerosis

FUS Proteinopathy in Frontotemporal Dementia

FUS Proteinopathy Neurons

FUS Protein

FUS Proteinopathy Pathway in ALS

FUS Proteinopathy

FUS Protein (Fused in Sarcoma)

FUS Protein-Targeting Therapy for ALS/FTD

FUS (Redirect)

Fused in Sarcoma (FUS) Protein

FUS-Mutant Motor Neurons

Pathway Diagram

Outgoing (1241)

Incoming (1166)

Targeting Hypotheses (30)

Mentioning Analyses (13)

Biophysical Determinants Shifting FUS/TDP-43 Phase Separation to Pathological Ag

Cell-Autonomous vs Non-Cell-Autonomous Mechanisms of Mutant FUS Neuromuscular De

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

How do host cell factors influence the conformation and propagation properties o

What determines the specificity of RNA-protein interactions that drive distinct

How does TRIM21-mediated K63 ubiquitination of G3BP1 mechanistically inhibit liq

How do pathological stress granules transition from reversible to persistent in

Blood-brain barrier antibody transport mechanisms

RNA binding protein dysregulation across ALS FTD and AD

Blood-brain barrier transport mechanisms for antibody therapeutics

RNA binding protein dysregulation across ALS FTD and AD

Experiments (0)

Related Papers (0)

Debates (15)

What are the biophysical determinants — RNA binding stoichiometry, post-translat

What are the relative contributions of cell-autonomous motor neuron mechanisms v

Debate: Liquid-to-Solid Transition Pathology Reveals Granule Weak Points

How does lncRNA-0021 achieve sequence-specific binding to mmu-miR-6361 and what

What mechanisms govern antibody transport across the blood-brain barrier and how

The study shows stress granules are dynamic and reversible assemblies, but in ne

The study shows that G3BP1 ubiquitination inhibits LLPS in vitro, but the molecu

While the study identifies G3BP1 as a central node triggering phase separation,

The abstract reveals FUS has a chaperone-like function regulating TAZ condensate

How does PIKFYVE inhibition activate unconventional protein clearance via exocyt

Related Research

Arginine Methylation Loss on FUS RGG Domains Drives Irreversible Phase Transitio

LDLR Ligand-Binding Domain A Fusion for Receptor-Mediated Transcytosis

Autophagosome-Lysosome Fusion Defects as Primary Driver of α-Synuclein Propagati

RNA-binding protein condensate maturation from reversible phase separation to am

mutant FUS effects split between motor-neuron intrinsic stress and glial/NMJ inf

Optogenetic viral vector delivery via tFUS-mediated blood-brain barrier opening

Designer TRAK1-KIF5 fusion proteins accelerate therapeutic mitochondrial deliver

FUS Mutations Alter Stress Granule Material Properties to Confer Autophagy Resis

Cell-state stratification is required to resolve Cell-Autonomous vs Non-Cell-Aut

Cell-state stratification is required to resolve Biophysical Determinants Shifti

Perturbation-first validation should precede therapeutic claims for Cell-Autonom

Perturbation-first validation should precede therapeutic claims for Biophysical

Cytosolic TDP-43 aggregation sequesters SNAP29 and syntaxin-17, blocking autopha